Olopatadine 0.2% for the Treatment of Allergic Conjunctivitis

A Comparative Study of Olopatadine 0.2% Versus Vehicle in Patients With Seasonal Allergic Conjunctivitis or Rhinoconjunctivitis

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00331500

Enrollment

287

Registered

2006-05-31

Start date

2006-04-18

Completion date

2006-07-27

Last updated

2017-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic Conjunctivitis

Brief summary

The purpose of this study is to demonstrate that Olopatadine 0.2% is superior to vehicle in the treatment of the signs and symptoms associated with allergic conjunctivitis or rhinoconjunctivitis.

Interventions

DRUGOlopatadine Hydrochloride Ophthalmic Solution, 0.2%

DRUGOlopatadine Hydrochloride Ophthalmic Solution Vehicle

Inactive ingredients used as a placebo comparator

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

10 Years to No maximum

Healthy volunteers

Inclusion criteria

* History of seasonal allergic conjunctivitis or rhinoconjunctivitis, a positive grass antigen challenge reaction (skin test), and a positive response to grass in the Conjunctival Allergen Challenge (CAC) model

Exclusion criteria

* Under 10 years of age

Design outcomes

Primary

Measure	Time frame
Daily ocular itching and redness scores	Up to Day 14

Secondary

Measure	Time frame
Percentage of patients with daily ocular itching and redness scores of 0	Up to Day 14

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026